Clinical Trials Logo

Cognitive Flexibility clinical trials

View clinical trials related to Cognitive Flexibility.

Filter by:
  • None
  • Page 1

NCT ID: NCT06267521 Recruiting - Clinical trials for Emotional Regulation

The STRENGTHEN Study

Start date: March 6, 2024
Phase: N/A
Study type: Interventional

This study uses two different types of interventions including electrical brain stimulation delivered during sleep, and brief, daily meditation training. The investigators are trying to figure out whether these techniques, either alone or in combination with each other, can positively impact the brain networks that support our ability to think flexibly and to regulate our emotions. 48 participants will be enrolled and can expect to be on study for up to 9 months.

NCT ID: NCT03462303 Completed - Clinical trials for Cognitive Flexibility

Modulation of Cognitive Flexibility by Tyrosine Depletion and Transcranial Direct Current Stimulation

Start date: February 12, 2018
Phase: N/A
Study type: Interventional

The dorsolateral prefrontal cortex (dlPFC) and dopamine (DA) have been implicated in the control of cognitive flexibility. However, while a great deal of what it is know regarding a causative relationship between cognitive flexibility and its neuronal underpinning comes from animal studies, human data have largely been correlational (i.e. imaging investigations). In a recent study, the current research group examined whether putative increases in dopamine levels through tyrosine administration and blockage of these by cathodal (i.e. inhibitory) transcranial direct current stimulation (tDCS) of the dlPFC could be causally related to cognitive flexibility as measured by task switching and reversal learning. The next step involves finding a way of lowering dopamine concentrations while anodal (i.e. excitatory) stimulation of the dlPFC is applied and cognitive flexibility measured. One experimental approach to reduce global DA synthesis and transmission is through acute phenylalanine and tyrosine depletion (APTD). This dietary intervention involves the administration of an amino-acid mixture lacking in tyrosine and phenylalanine, which can be used to selectively lower DA synthesis in humans.